SlideShare a Scribd company logo
1 of 42
⚫ Obstructive lung disease is a category of respiratory
disease characterized by airway obstruction. Many
obstructive diseases of the lung result from narrowing of
the smaller bronchi and larger bronchioles, often because
of excessive contraction of the smooth muscle itself. It is
generally characterized by inflamed and easily collapsible
airways, obstruction to airflow, problems exhaling and
frequent medical clinic visits and hospitalizations.
⚫ Types of obstructive lung disease include; asthma,
bronchiectasis, bronchitis and chronic obstructive
pulmonary disease (COPD). Although COPD shares
similar characteristics with all other obstructive lung
diseases, such as the signs of coughing and wheezing,
they are distinct conditions in terms of disease onset,
frequency of symptoms and reversibility of airway
obstruction.Cystic fibrosis is also sometimes included in
obstructive pulmonary disease.
⦿COPD is also known as chronic obstructive
lung disease (COLD), chronic obstructive
airway disease (COAD), chronic airflow
limitation (CAL) and chronic obstructive
respiratory disease (CORD)
⦿Chronic obstructive pulmonary disease (COPD)
refers to chronic bronchitis and emphysema, a
pair of two commonly co-existing diseases of
the lungs in which the airways become
narrowed. This leads to a limitation of the
flow of
⦿ air to and from the lungs causing
⦿ shortness of breath.
⦿In COPD, less air flows in and out of the
airways because of one or more of the
following:
 The airways and air sacs lose their
elastic quality.
 The walls between many of the air sacs
are destroyed.
 The walls of the airways become thick
and inflamed.
 The airways make more mucus than
usual, which tends to clog them.
Gross pathology of lung showing centrilobular emphysema
characteristic of smoking. Closeup of fixed, cut surface shows
multiple cavities lined by heavy black carbon deposits.
⦿ 1)Smoking
⦿2) Occupational exposures- exposure to
workplace dusts found in coal mining, gold
mining, and the cotton textile industry and
chemicals such as cadmium, isocyanates, and
fumes from welding have been implicated in
the development of airflow obstruction.
⦿ 3) Air pollution
⦿ 4) sudden airway constriction in response to
inhaled irritants,
⦿5) Bronchial hyperresponsiveness, is a
characteristic of asthma.
⦿6) Genetics-Alpha 1-antitrypsin deficiency
is a genetic condition that is responsible
for about 2% of cases of COPD. In this
condition, the body does not make enough
of a protein, alpha 1-antitrypsin. Alpha 1-
antitrypsin protects the lungs from
damage caused by protease enzymes, such
as elastase and trypsin, that can be
released as a result of an inflammatory
response to tobacco smoke.
NUTRITION
INFECTIONS
SOCIO ECONOMIC ST
A
TUS
AGING POPULATION
Risk factors
• Most cases of COPD are caused by
inhaling pollutants; that includes smoking
(cigarettes, pipes, cigars, etc.), and
second-hand smoke.
• Fumes, chemicals and dust found in
many work environments are contributing
factors for many individuals who develop
COPD.
• Genetics can also play a role in an
individual’s development of COPD—even
if the person has never smoked or has
ever been exposed to strong lung irritants
⦿Abnormal inflammatory response of the
lungs due to toxic gases.
⦿ Response occurs in the airways
,parenchyma & pulmonary vasculature.
⦿ Narrowing of the airway takes place
⦿ Destruction of parenchyma leads to
emphysema.
⦿Destruction of lung parenchyma leads to an
imbalance of proteinases/antiproteinases.
(this proteinases inhibitors prevents the
destructive process)
⦿ Pulmonary vascularchanges
 Thickening of vessels
 Collagen deposit
 Destruction of capillary beds.
⦿
Mucus hypersecretion(cilia dysfunction,airflow
limitation,corpulmonale(RVF))
⦿
⦿
Chronic cough and sputum production
Stages of COPD
Mild COPD or Stage 1—Mild COPD with
a FEV1 about 80 percent or more of
normal.
Moderate COPD or Stage 2—Moderate
COPD with a FEV1 between 50 and 80
percent of normal.
Severe COPD or Stage 3—Severe
emphysema with a FEV1 between 30 and
50 percent of normal.
Very Severe COPD or Stage 4—Very
severe or End-Stage COPD with a lower
FEV1 than Stage 3, or people with low
 Chronic cough
 Sputum production
 Wheezing
 Chest tightness
 Dyspnoea on exertion
 Wt.loss
 Respiratory insufficiency
 Respiratory infections
 Barrel chest- chronic hyperinflation leads
to loss of lung elasticity.
• The most common symptoms of COPD are
• sputum production,
• shortness of breath
• and a productive cough.
• These symptoms are present for a prolonged
period of time and typically worsen over time.It is
unclear if different types of COPD exist.While
previously divided into emphysema and chronic
bronchitis, emphysema is only a description of
lung changes rather than a disease itself, and
chronic bronchitis is simply a descriptor of
symptoms that may or may not occur with COPD
⚫ Cough
⚫ A chronic cough is often the first symptom to develop.
When it persists for more than three months each year for
at least two years, in combination with sputum production,
there is by definition chronic bronchitis.
⚫ This condition can occur before COPD fully develops. The
amount of sputum produced can change over hours to
days. In some cases, the cough may not be present or may
only occur occasionally and may not be productive. Some
people with COPD attribute the symptoms to a "smoker's
cough".
⚫ Sputum may be swallowed or spat out, depending often on
social and cultural factors.
⚫ Vigorous coughing may lead to rib fractures or a brief loss of
consciousness. Those with COPD often have a history of
"common colds" that last a long time.
⚫Shortness of breath
⚫Shortness of breath is often the symptom that
most bothers people.I t is commonly described
as: "my breathing requires effort," "I feel out of
breath," or "I can't get enough air in".
⚫the shortness of breath is worse on exertion of a
prolonged duration and worsens over time.In the
advanced stages, it occurs during rest and may
be always present. It is a source of both anxiety
and a poor quality of life in those with COPD.
Many people with more advanced COPD breathe
through pursed lips and this action can improve
shortness of breath in some.
⚫ Other features
⚫ In COPD, it may take longer to breathe out than to breathe in.
Chest tightness may occur.Those with obstructed airflow may
have wheezing or decreased sounds with air entry on
examination of the chest with a stethoscope.
⚫ A barrel chest is a characteristic sign of COPD, but is
relatively uncommon.
⚫ Tripod positioning may occur as the disease worsens.
⚫ Advanced COPD leads to high pressure on the lung arteries,
which strains the right ventricle of the heart.This situation is
referred to as cor pulmonale, and leads to symptoms of leg
swelling and bulging neck veins.
⚫ Cor pulmonale has become less common since the use of
supplemental oxygen.
⚫ Fingernail clubbing is not specific to COPD and should
prompt investigations for an underlying lung cancer.
⚫Exacerbation
⚫An acute exacerbation of COPD is defined as
increased shortness of breath, increased sputum
production, a change in the color of the sputum
from clear to green or yellow, or an increase in
cough in someone with COPD.
⚫This may present with signs of increased work of
breathing such as fast breathing, a fast heart
rate, sweating, active use of muscles in the neck,
a bluish tinge to the skin, and confusion or
combative behavior in very severe
exacerbations.Crackles may also be heard over
the lungs on examination with a stethoscope.
diagnosis
• The diagnosis of COPD should be considered in
anyone over the age of 35 to 40 who has
shortness of breath, a chronic cough, sputum
production, or frequent winter colds and a history
of exposure to risk factors for the disease.
Spirometry is then used to confirm the diagnosis.
Screening those without symptoms is not
recommended.
• Lung function test
• ABG analysis
• Pulse oximetry
• Alpha 1 antitrypsin level
• Spirometry
• Spirometry measures the amount of airflow
obstruction present and is generally carried out after
the use of a bronchodilator .
• Two main components are measured to make the
diagnosis: the forced expiratory volume in one
second (FEV1), which is the greatest volume of air
that can be breathed out in the first second of a
breath, and the forced vital capacity(FVC), which is
the greatest volume of air that can be breathed out
in a single large breath.
• Normally, 75–80% of the FVC comes out in the first
secondand a FEV1/FVC ratio of less than 70% in
someone with symptoms of COPD defines a person
as having the disease.
⚫Other tests
⚫chest X-ray - Characteristic signs on X-ray are
overexpanded lungs, a flattened diaphragm, increased
retrosternal airspace, and bullae while it can help
exclude other lung diseases, such as pneumonia,
pulmonary edema or a pneumothorax.
⚫complete blood count
⚫ A high-resolution computed tomography scan of the
chest may show the distribution of emphysema
throughout the lungs and can also be useful to exclude
other lung diseases.
⚫An analysis of arterial blood is used to determine the
need for oxygen; this is recommended in those with an
FEV1 less than 35% predicted, those with a peripheral
oxygen saturation of less than 92% and those with
⚫ Management
⚫no known cure for COPD, but the symptoms
are treatable and its progression can be
delayed
⚫smoking cessation and supplemental oxygen
⚫Stopping smoking decreases the risk of death
by 18%.
⚫ influenza vaccination once a year,
pneumococcal vaccination once every five
years, and reduction in exposure to
environmental air pollution.
⚫ In those with advanced disease, palliative care
may reduce symptoms, with morphine
⚫ Exercise
• Pulmonary rehabilitation - exercise, disease management
and counseling
• Breathing exercises & Pursed lip breathing exercises
⚫ Bronchodilators
• Inhaled bronchodilators
• two major types, β
2agonists and anticholinergics; They
reduce shortness of breath, wheeze and exercise limitation,
resulting in an improved quality of life.
• If long-acting bronchodilators are insufficient, then inhaled
corticosteroids are typically added. tiotropium (a long-acting
anticholinergic) or long-acting beta agonists (LABAs)
• short-acting β
2agonists - salbutamol (albuterol) and
terbutaline , provide some relief of symptoms for four to six
hours
• Long-acting β
2agonists - salmeterol, formoterol and
indacaterol
• two main anticholinergics, ipratropium and tiotropium.
• Aclidinium, another long acting agent, reduces
⚫Other medication
⚫Long-term antibiotics - macrolide class such as
erythromycin, reduce the frequency of
exacerbations in those who have two or more a
year.
⚫ Methylxanthines such as theophylline generally
cause more harm than benefit and thus are
usually not recommended, but may be used as
a second-line agent in those not controlled by
other measures.
⚫ Mucolytics may help to reduce exacerbations in
some people with chronic bronchitis.
⚫ Cough medicines are not recommended
⚫Oxygen
⚫Supplemental oxygen - low oxygen levels at rest (a
partial pressure of oxygen of less than 50–55 mmHg
or oxygen saturations of less than 88%).
⚫oxygen supplementation may improve shortness of
breath when given during exercise, but may not
improve breathlessness during normal daily activities
or impact the quality of life
⚫Surgery
⚫lung transplantation or lung volume reduction
surgery.
⚫Lung volume reduction surgery involves removing the
parts of the lung most damaged by emphysema
allowing the remaining, relatively good lung to
expand and work better.
• Exacerbations
• Acute exacerbations - short-acting bronchodilators
or combination of a short-acting inhaled beta
agonist and anticholinergic , can be given either
via a metered-dose inhaler with a spacer or via a
nebulizer with both appearing to be equally
effective
• Nebulization
• Oxygen supplementation
• Corticosteroids
• antibiotics - amoxicillin, doxycycline and
azithromycin
 Respiratory insufficiency
 Respiratory failure
 Pneumonia
 Atelectasis
 Pneumothorax
 Pulmonary artery hypertension.
 Status asthmaticus
 hypoxemia
 respiratory infections, including colds, flu
 heart problems
 lung cancer
Complications
• Respiratory acidosis
• Corpulmonale
• Dysrhythmias
• Skeletal muscle depression
⦿TAKE YOUR MEDICATIONS REGULARLY AS
PRESCRIBED,IF YOU HAVE ANY DOUBT RING
YOUR HOSPITAL.
⦿ EXERCISE REGULARL
Y EVERYDA
Y OR ELSE
ATLEAST 4 OUT OF 7 DAYS.
THANK YOU!

More Related Content

Similar to copd-180104083331.pptx

copdaslam-160531103105.pdf
copdaslam-160531103105.pdfcopdaslam-160531103105.pdf
copdaslam-160531103105.pdfAbdrahmanDOKMAK1
 
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamCOPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamDr.Aslam calicut
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Rahil Dalal
 
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...balajinandhan9447242
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptx
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptxCHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptx
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptxshiwani88
 
Chronic Obstructive pulmonary Disease
Chronic Obstructive pulmonary DiseaseChronic Obstructive pulmonary Disease
Chronic Obstructive pulmonary DiseaseDipali Dumbre
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseDrRavi Jain
 
Chronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxChronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxSerenaRambaran1
 

Similar to copd-180104083331.pptx (20)

copdaslam-160531103105.pdf
copdaslam-160531103105.pdfcopdaslam-160531103105.pdf
copdaslam-160531103105.pdf
 
Copd
CopdCopd
Copd
 
COPD.pptx
COPD.pptxCOPD.pptx
COPD.pptx
 
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslamCOPD  (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
COPD (Chronic obstructive Pulmonary Disease) PowerPoint Presentation -aslam
 
COPD -MA.pptx
COPD -MA.pptxCOPD -MA.pptx
COPD -MA.pptx
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)
 
2 COPD.ppt
2  COPD.ppt2  COPD.ppt
2 COPD.ppt
 
COPD
COPDCOPD
COPD
 
Copd presentation dickson bns 3
Copd  presentation  dickson bns 3Copd  presentation  dickson bns 3
Copd presentation dickson bns 3
 
COPD.pdf
COPD.pdfCOPD.pdf
COPD.pdf
 
Copd
CopdCopd
Copd
 
Copd
CopdCopd
Copd
 
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...
ctyuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuoipppopd-2201011...
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptx
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptxCHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptx
CHRONIC OBSTRUCTIVE PULMONARY DISEASE.pptx
 
Copd
CopdCopd
Copd
 
Copd
CopdCopd
Copd
 
Chronic Obstructive pulmonary Disease
Chronic Obstructive pulmonary DiseaseChronic Obstructive pulmonary Disease
Chronic Obstructive pulmonary Disease
 
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
 
Copd
CopdCopd
Copd
 
Chronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptxChronic Obstructive Pulmonary Disease (COPD).pptx
Chronic Obstructive Pulmonary Disease (COPD).pptx
 

More from NanditaHalder3

acute respiratory distress syndrome.pptx
acute respiratory distress syndrome.pptxacute respiratory distress syndrome.pptx
acute respiratory distress syndrome.pptxNanditaHalder3
 
Childhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxChildhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxNanditaHalder3
 
Childhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxChildhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxNanditaHalder3
 
Fluid, electrolyte and acid – base balances.pptx
Fluid, electrolyte and acid – base balances.pptxFluid, electrolyte and acid – base balances.pptx
Fluid, electrolyte and acid – base balances.pptxNanditaHalder3
 
Care of Dying Patient.docx
Care of Dying Patient.docxCare of Dying Patient.docx
Care of Dying Patient.docxNanditaHalder3
 
ETHICO LEGAL ISSUES.pptx
ETHICO LEGAL ISSUES.pptxETHICO LEGAL ISSUES.pptx
ETHICO LEGAL ISSUES.pptxNanditaHalder3
 

More from NanditaHalder3 (10)

INFLAMMATION.pptx
INFLAMMATION.pptxINFLAMMATION.pptx
INFLAMMATION.pptx
 
acute respiratory distress syndrome.pptx
acute respiratory distress syndrome.pptxacute respiratory distress syndrome.pptx
acute respiratory distress syndrome.pptx
 
Childhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxChildhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptx
 
Childhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptxChildhood Acute Leukemia.pptx
Childhood Acute Leukemia.pptx
 
INFLAMMATION.pptx
INFLAMMATION.pptxINFLAMMATION.pptx
INFLAMMATION.pptx
 
Fluid, electrolyte and acid – base balances.pptx
Fluid, electrolyte and acid – base balances.pptxFluid, electrolyte and acid – base balances.pptx
Fluid, electrolyte and acid – base balances.pptx
 
Care of Dying Patient.docx
Care of Dying Patient.docxCare of Dying Patient.docx
Care of Dying Patient.docx
 
NIS.pptx
NIS.pptxNIS.pptx
NIS.pptx
 
NIS.pptx
NIS.pptxNIS.pptx
NIS.pptx
 
ETHICO LEGAL ISSUES.pptx
ETHICO LEGAL ISSUES.pptxETHICO LEGAL ISSUES.pptx
ETHICO LEGAL ISSUES.pptx
 

Recently uploaded

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Celine George
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxEyham Joco
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaVirag Sontakke
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxsocialsciencegdgrohi
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 

Recently uploaded (20)

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptx
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of India
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 

copd-180104083331.pptx

  • 1.
  • 2. ⚫ Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling and frequent medical clinic visits and hospitalizations. ⚫ Types of obstructive lung disease include; asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms and reversibility of airway obstruction.Cystic fibrosis is also sometimes included in obstructive pulmonary disease.
  • 3. ⦿COPD is also known as chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD) ⦿Chronic obstructive pulmonary disease (COPD) refers to chronic bronchitis and emphysema, a pair of two commonly co-existing diseases of the lungs in which the airways become narrowed. This leads to a limitation of the flow of ⦿ air to and from the lungs causing ⦿ shortness of breath.
  • 4.
  • 5. ⦿In COPD, less air flows in and out of the airways because of one or more of the following:  The airways and air sacs lose their elastic quality.  The walls between many of the air sacs are destroyed.  The walls of the airways become thick and inflamed.  The airways make more mucus than usual, which tends to clog them.
  • 6.
  • 7.
  • 8. Gross pathology of lung showing centrilobular emphysema characteristic of smoking. Closeup of fixed, cut surface shows multiple cavities lined by heavy black carbon deposits.
  • 9. ⦿ 1)Smoking ⦿2) Occupational exposures- exposure to workplace dusts found in coal mining, gold mining, and the cotton textile industry and chemicals such as cadmium, isocyanates, and fumes from welding have been implicated in the development of airflow obstruction. ⦿ 3) Air pollution ⦿ 4) sudden airway constriction in response to inhaled irritants, ⦿5) Bronchial hyperresponsiveness, is a characteristic of asthma.
  • 10. ⦿6) Genetics-Alpha 1-antitrypsin deficiency is a genetic condition that is responsible for about 2% of cases of COPD. In this condition, the body does not make enough of a protein, alpha 1-antitrypsin. Alpha 1- antitrypsin protects the lungs from damage caused by protease enzymes, such as elastase and trypsin, that can be released as a result of an inflammatory response to tobacco smoke.
  • 12. Risk factors • Most cases of COPD are caused by inhaling pollutants; that includes smoking (cigarettes, pipes, cigars, etc.), and second-hand smoke. • Fumes, chemicals and dust found in many work environments are contributing factors for many individuals who develop COPD. • Genetics can also play a role in an individual’s development of COPD—even if the person has never smoked or has ever been exposed to strong lung irritants
  • 13. ⦿Abnormal inflammatory response of the lungs due to toxic gases. ⦿ Response occurs in the airways ,parenchyma & pulmonary vasculature. ⦿ Narrowing of the airway takes place ⦿ Destruction of parenchyma leads to emphysema.
  • 14. ⦿Destruction of lung parenchyma leads to an imbalance of proteinases/antiproteinases. (this proteinases inhibitors prevents the destructive process) ⦿ Pulmonary vascularchanges  Thickening of vessels  Collagen deposit  Destruction of capillary beds. ⦿ Mucus hypersecretion(cilia dysfunction,airflow limitation,corpulmonale(RVF)) ⦿ ⦿ Chronic cough and sputum production
  • 15.
  • 16. Stages of COPD Mild COPD or Stage 1—Mild COPD with a FEV1 about 80 percent or more of normal. Moderate COPD or Stage 2—Moderate COPD with a FEV1 between 50 and 80 percent of normal. Severe COPD or Stage 3—Severe emphysema with a FEV1 between 30 and 50 percent of normal. Very Severe COPD or Stage 4—Very severe or End-Stage COPD with a lower FEV1 than Stage 3, or people with low
  • 17.  Chronic cough  Sputum production  Wheezing  Chest tightness  Dyspnoea on exertion  Wt.loss  Respiratory insufficiency  Respiratory infections  Barrel chest- chronic hyperinflation leads to loss of lung elasticity.
  • 18. • The most common symptoms of COPD are • sputum production, • shortness of breath • and a productive cough. • These symptoms are present for a prolonged period of time and typically worsen over time.It is unclear if different types of COPD exist.While previously divided into emphysema and chronic bronchitis, emphysema is only a description of lung changes rather than a disease itself, and chronic bronchitis is simply a descriptor of symptoms that may or may not occur with COPD
  • 19. ⚫ Cough ⚫ A chronic cough is often the first symptom to develop. When it persists for more than three months each year for at least two years, in combination with sputum production, there is by definition chronic bronchitis. ⚫ This condition can occur before COPD fully develops. The amount of sputum produced can change over hours to days. In some cases, the cough may not be present or may only occur occasionally and may not be productive. Some people with COPD attribute the symptoms to a "smoker's cough". ⚫ Sputum may be swallowed or spat out, depending often on social and cultural factors. ⚫ Vigorous coughing may lead to rib fractures or a brief loss of consciousness. Those with COPD often have a history of "common colds" that last a long time.
  • 20. ⚫Shortness of breath ⚫Shortness of breath is often the symptom that most bothers people.I t is commonly described as: "my breathing requires effort," "I feel out of breath," or "I can't get enough air in". ⚫the shortness of breath is worse on exertion of a prolonged duration and worsens over time.In the advanced stages, it occurs during rest and may be always present. It is a source of both anxiety and a poor quality of life in those with COPD. Many people with more advanced COPD breathe through pursed lips and this action can improve shortness of breath in some.
  • 21. ⚫ Other features ⚫ In COPD, it may take longer to breathe out than to breathe in. Chest tightness may occur.Those with obstructed airflow may have wheezing or decreased sounds with air entry on examination of the chest with a stethoscope. ⚫ A barrel chest is a characteristic sign of COPD, but is relatively uncommon. ⚫ Tripod positioning may occur as the disease worsens. ⚫ Advanced COPD leads to high pressure on the lung arteries, which strains the right ventricle of the heart.This situation is referred to as cor pulmonale, and leads to symptoms of leg swelling and bulging neck veins. ⚫ Cor pulmonale has become less common since the use of supplemental oxygen. ⚫ Fingernail clubbing is not specific to COPD and should prompt investigations for an underlying lung cancer.
  • 22. ⚫Exacerbation ⚫An acute exacerbation of COPD is defined as increased shortness of breath, increased sputum production, a change in the color of the sputum from clear to green or yellow, or an increase in cough in someone with COPD. ⚫This may present with signs of increased work of breathing such as fast breathing, a fast heart rate, sweating, active use of muscles in the neck, a bluish tinge to the skin, and confusion or combative behavior in very severe exacerbations.Crackles may also be heard over the lungs on examination with a stethoscope.
  • 23. diagnosis • The diagnosis of COPD should be considered in anyone over the age of 35 to 40 who has shortness of breath, a chronic cough, sputum production, or frequent winter colds and a history of exposure to risk factors for the disease. Spirometry is then used to confirm the diagnosis. Screening those without symptoms is not recommended. • Lung function test • ABG analysis • Pulse oximetry • Alpha 1 antitrypsin level
  • 24. • Spirometry • Spirometry measures the amount of airflow obstruction present and is generally carried out after the use of a bronchodilator . • Two main components are measured to make the diagnosis: the forced expiratory volume in one second (FEV1), which is the greatest volume of air that can be breathed out in the first second of a breath, and the forced vital capacity(FVC), which is the greatest volume of air that can be breathed out in a single large breath. • Normally, 75–80% of the FVC comes out in the first secondand a FEV1/FVC ratio of less than 70% in someone with symptoms of COPD defines a person as having the disease.
  • 25. ⚫Other tests ⚫chest X-ray - Characteristic signs on X-ray are overexpanded lungs, a flattened diaphragm, increased retrosternal airspace, and bullae while it can help exclude other lung diseases, such as pneumonia, pulmonary edema or a pneumothorax. ⚫complete blood count ⚫ A high-resolution computed tomography scan of the chest may show the distribution of emphysema throughout the lungs and can also be useful to exclude other lung diseases. ⚫An analysis of arterial blood is used to determine the need for oxygen; this is recommended in those with an FEV1 less than 35% predicted, those with a peripheral oxygen saturation of less than 92% and those with
  • 26. ⚫ Management ⚫no known cure for COPD, but the symptoms are treatable and its progression can be delayed ⚫smoking cessation and supplemental oxygen ⚫Stopping smoking decreases the risk of death by 18%. ⚫ influenza vaccination once a year, pneumococcal vaccination once every five years, and reduction in exposure to environmental air pollution. ⚫ In those with advanced disease, palliative care may reduce symptoms, with morphine
  • 27. ⚫ Exercise • Pulmonary rehabilitation - exercise, disease management and counseling • Breathing exercises & Pursed lip breathing exercises ⚫ Bronchodilators • Inhaled bronchodilators • two major types, β 2agonists and anticholinergics; They reduce shortness of breath, wheeze and exercise limitation, resulting in an improved quality of life. • If long-acting bronchodilators are insufficient, then inhaled corticosteroids are typically added. tiotropium (a long-acting anticholinergic) or long-acting beta agonists (LABAs) • short-acting β 2agonists - salbutamol (albuterol) and terbutaline , provide some relief of symptoms for four to six hours • Long-acting β 2agonists - salmeterol, formoterol and indacaterol • two main anticholinergics, ipratropium and tiotropium. • Aclidinium, another long acting agent, reduces
  • 28. ⚫Other medication ⚫Long-term antibiotics - macrolide class such as erythromycin, reduce the frequency of exacerbations in those who have two or more a year. ⚫ Methylxanthines such as theophylline generally cause more harm than benefit and thus are usually not recommended, but may be used as a second-line agent in those not controlled by other measures. ⚫ Mucolytics may help to reduce exacerbations in some people with chronic bronchitis. ⚫ Cough medicines are not recommended
  • 29. ⚫Oxygen ⚫Supplemental oxygen - low oxygen levels at rest (a partial pressure of oxygen of less than 50–55 mmHg or oxygen saturations of less than 88%). ⚫oxygen supplementation may improve shortness of breath when given during exercise, but may not improve breathlessness during normal daily activities or impact the quality of life ⚫Surgery ⚫lung transplantation or lung volume reduction surgery. ⚫Lung volume reduction surgery involves removing the parts of the lung most damaged by emphysema allowing the remaining, relatively good lung to expand and work better.
  • 30. • Exacerbations • Acute exacerbations - short-acting bronchodilators or combination of a short-acting inhaled beta agonist and anticholinergic , can be given either via a metered-dose inhaler with a spacer or via a nebulizer with both appearing to be equally effective • Nebulization • Oxygen supplementation • Corticosteroids • antibiotics - amoxicillin, doxycycline and azithromycin
  • 31.  Respiratory insufficiency  Respiratory failure  Pneumonia  Atelectasis  Pneumothorax  Pulmonary artery hypertension.  Status asthmaticus  hypoxemia  respiratory infections, including colds, flu  heart problems  lung cancer
  • 32. Complications • Respiratory acidosis • Corpulmonale • Dysrhythmias • Skeletal muscle depression
  • 33.
  • 34. ⦿TAKE YOUR MEDICATIONS REGULARLY AS PRESCRIBED,IF YOU HAVE ANY DOUBT RING YOUR HOSPITAL. ⦿ EXERCISE REGULARL Y EVERYDA Y OR ELSE ATLEAST 4 OUT OF 7 DAYS.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.